checkAd

     145  0 Kommentare Capricor Therapeutics to Present at Upcoming Investor Conferences

    SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, today announced that the Company is scheduled to present at two upcoming investor conferences.

    Event: H.C. Wainwright 2nd Annual Cell Therapy Conference
    Presentation: March 26, 2024 at 2:00 p.m. ET
    Format: Virtual fireside chat and one-on-one meetings
       
    Event: Cantor Fitzgerald’s Muscular Dystrophy Symposium
    Presentation: April 3, 2024 at 1:30 p.m. ET
    Format: Virtual fireside chat
       

    Dr. Linda Marbán, Capricor’s chief executive officer will present updates on Capricor’s recent progress on its lead program of CAP-1002 for the treatment of Duchenne muscular dystrophy (DMD) as well as other general scientific and corporate updates. For more information on these presentations, please visit Capricor's website at http://capricor.com/news/events/.

    About Capricor Therapeutics

    Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, CAP-1002 — an allogeneic cardiac-derived cell therapy. Extensive preclinical and clinical studies have shown CAP-1002 to demonstrate immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. CAP-1002 is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). Capricor is also harnessing the power of our exosome technology, using our proprietary StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases. At Capricor, we stand committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. For more information, visit capricor.com, and follow Capricor on FacebookInstagram and Twitter.

    Seite 1 von 3



    Diskutieren Sie über die enthaltenen Werte



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Capricor Therapeutics to Present at Upcoming Investor Conferences SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) - Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, today announced that the …